Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

pancreatic insulin-producing neuroendocrine tumor - Clinical Profile, Genes & Research | Kisho | Kisho

Organ System	Phenotype Count	Example Features
Brain and nerves	7	Atypical behavior, Anxiety, Seizure
Eyes	2	Abnormality of vision, Abnormal rapid eye movement sleep
Digestive system	2	Excessive hunger (polyphagia), Abnormality of the pancreatic islet cells
Hormones	2	Pituitary prolactin cell adenoma, Neoplasm of the adrenal gland
Ears	1	Hearing abnormality
Skin	1	Excessive sweating (hyperhidrosis)
Muscles	1	Generalized muscle weakness
Cognition	1	Abnormality of mental function

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.

140 publications have been identified in PubMed for pancreatic insulin-producing neuroendocrine tumor. Research spans Basic Science / Preclinical (41%), Case Report / Case Series (15%), and Review / Meta-Analysis (13%).

Research Type	Count	% of Total
Laboratory research	58	41%
Patient case studies	21	15%
Research summaries	18	13%
Testing and diagnosis research	16	11%
Clinical study results	13	9%
New treatment approaches	10	7%
Disease patterns and progression	3	2%
Other research	1	1%

Recent Publications

Vujasinovic M (2026). [PMID: 41689768](https://pubmed.ncbi.nlm.nih.gov/41689768/). *United European Gastroenterol J*. [Review / Meta-Analysis]
Helbing A (2026). [PMID: 28846270](https://pubmed.ncbi.nlm.nih.gov/28846270/). *Unknown Journal*. [Diagnostic / Biomarker]
Kobayashi H (2026). [PMID: 41474982](https://pubmed.ncbi.nlm.nih.gov/41474982/). *Cancer Res*. [Basic Science / Preclinical]
Zhuo F (2026). [PMID: 31335019](https://pubmed.ncbi.nlm.nih.gov/31335019/). *Unknown Journal*. [Case Report / Case Series]
van Baal L (2026). [PMID: 41448958](https://pubmed.ncbi.nlm.nih.gov/41448958/). *Diabetes Obes Metab*. [Diagnostic / Biomarker]
Jacobsen LM (2026). [PMID: 41697686](https://pubmed.ncbi.nlm.nih.gov/41697686/). *JAMA*. [Clinical Trial Publication]
Wei F (2026). [PMID: 41850539](https://pubmed.ncbi.nlm.nih.gov/41850539/). *Gastroenterology*. [Basic Science / Preclinical]
Awad DH (2026). [PMID: 31194450](https://pubmed.ncbi.nlm.nih.gov/31194450/). *Unknown Journal*. [Other]
Li H (2026). [PMID: 41235536](https://pubmed.ncbi.nlm.nih.gov/41235536/). *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*. [Basic Science / Preclinical]
Li Z (2026). [PMID: 41519441](https://pubmed.ncbi.nlm.nih.gov/41519441/). *J Nutr Biochem*. [Basic Science / Preclinical]

Kisho

pancreatic insulin-producing neuroendocrine tumor

Overview

Clinical Presentation

Explore clinical features

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Latest News & Developments

Clinicopathological features and outcomes of immature PIT-1 lineage tumors: A high-risk pituitary neuroendocrine tumor/pituitary adenoma subtype per WHO 2022.

Life-Threatening Radiation Necrosis After Complete Response to Pembrolizumab in a Patient With a Metastatic Silent PIT1 Pituitary Neuroendocrine Tumor (PitNET).

pancreatic insulin-producing neuroendocrine tumor

Overview

Clinical Presentation

Explore clinical features

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Latest News & Developments

Clinicopathological features and outcomes of immature PIT-1 lineage tumors: A high-risk pituitary neuroendocrine tumor/pituitary adenoma subtype per WHO 2022.

Life-Threatening Radiation Necrosis After Complete Response to Pembrolizumab in a Patient With a Metastatic Silent PIT1 Pituitary Neuroendocrine Tumor (PitNET).